Essential Partners’s C4 Therapeutics CCCC Stock Holding History

Essential Partners’s Portfolio CCCC Stock Details CCCC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-133	Closed	-$190	–	2688
2025 Q2	$190	Buy	+133	New	+$193	﹤0.01%	1957

Other funds holding CCCC

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Essential Partners's CCCC Position: Q3 2025 in Review

Essential Partners sold out of C4 Therapeutics (CCCC) in Q3 2025, closing a stake of 133 shares — an estimated $190 sold.

Essential Partners first reported a position in CCCC in Q2 2025 and held it in 1 quarter. The position peaked at $190 in Q2 2025. 97 funds tracked by Wall St. Rank hold CCCC as of Q3 2025.

Essential Partners reported no remaining C4 Therapeutics position as of Q3 2025 after selling out during the quarter.
Essential Partners sold 133 C4 Therapeutics shares in Q3 2025, an estimated $190.
Essential Partners first reported a position in C4 Therapeutics in Q2 2025 and held it in 1 quarter.
Essential Partners's C4 Therapeutics position peaked at $190 in Q2 2025.
97 funds tracked by Wall St. Rank held C4 Therapeutics as of Q3 2025.

Based on Essential Partners's 13F filing for Q3 2025, filed 21 May 2026.